Chronic pain syndromes affect an estimated 20–30% of the global population, imposing a massive burden on individuals and healthcare systems. Unlike acute pain, which serves as a protective warning signal following injury, chronic pain persists for months or years beyond the expected healing period, often without an identifiable ongoing tissue threat. Understanding why pain becomes chronic requires a deep dive into the underlying biological and neurological processes. Physiological models provide a framework for dissecting these mechanisms, focusing on how the nervous, immune, and endocrine systems interact to sustain pain. This article explores the key physiological mechanisms of chronic pain, including nerve sensitization, neuroinflammation, neuroplastic changes, and peripheral drivers. By examining these models, clinicians and researchers can better target treatments that address root causes rather than simply masking symptoms.

The Biological Basis of Chronic Pain: Beyond Tissue Damage

Pain typically results from activation of nociceptors—specialized nerve endings that detect harmful stimuli such as heat, pressure, or chemical irritants. In acute pain, once the tissue heals, nociceptor activity subsides. However, in chronic pain syndromes, the nociceptive system becomes dysfunctional. Physiological models propose that pain persists due to maladaptive changes at multiple levels of the nervous system: peripheral nerves, spinal cord, brainstem, and cortical regions. These changes can be triggered by initial injury, infection, inflammation, or even genetic predispositions, but they become self‐sustaining over time.

The distinction between nociceptive (caused by ongoing tissue damage), neuropathic (caused by damage to the nervous system), and nociplastic (altered nociception without clear tissue or nerve damage) pain is central to modern physiological models. Many chronic pain syndromes—such as fibromyalgia, chronic low back pain, irritable bowel syndrome, and complex regional pain syndrome (CRPS)—show features of nociplastic pain, where the nervous system amplifies and maintains pain signals in the absence of obvious peripheral pathology. Understanding these distinctions helps guide treatment selection and research into novel interventions.

Key Physiological Mechanisms in Chronic Pain Syndromes

Several interconnected mechanisms contribute to the persistence and amplification of pain. These processes are not mutually exclusive and often co‐occur, creating a complex physiological milieu that varies by syndrome and individual.

Peripheral Sensitization

Peripheral sensitization occurs when nociceptors at the site of injury become hypersensitive due to chemical mediators released by damaged cells and immune cells. Substances such as prostaglandins, bradykinin, substance P, and cytokines lower the activation threshold of nociceptors, so normally innocuous stimuli (e.g., light touch or movement) can provoke pain (allodynia). In chronic conditions like osteoarthritis or peripheral neuropathy, persistent inflammation or nerve damage keeps nociceptors in a hyperexcitable state, continuously sending signals to the spinal cord. This ongoing barrage can then trigger central sensitization.

Central Sensitization

Central sensitization is a maladaptive amplification of pain processing within the spinal cord and brain. Repeated or intense nociceptive input causes synaptic plasticity in dorsal horn neurons—changes that increase their responsiveness to both noxious and non‐noxious stimuli. Key mechanisms include long‐term potentiation (LTP) of pain pathways, reduced inhibition from descending modulatory systems, and altered expression of neurotransmitter receptors (e.g., NMDA receptors). Once established, central sensitization can maintain pain even after peripheral input subsides. This phenomenon is a hallmark of many chronic pain syndromes and explains why pain can spread to regions beyond the original injury site.

Neuroinflammation and Glial Activation

Neuroinflammation refers to the activation of immune cells within the central nervous system—particularly microglia and astrocytes—in response to nerve injury or persistent pain signals. These glial cells release pro‐inflammatory cytokines (e.g., IL‐1β, TNF‐α, IL‐6), chemokines, and reactive oxygen species that further sensitize neurons and promote central sensitization. Unlike the classic inflammation of peripheral tissues, neuroinflammation can become chronic and self‐perpetuating, contributing to pain persistence and associated symptoms like fatigue, sleep disturbance, and cognitive dysfunction. Research has shown glial activation in conditions such as fibromyalgia, chronic low back pain, and migraine.

Altered Pain Pathways and Supraspinal Processing

In chronic pain, the balance between descending inhibitory and descending facilitatory pathways from the brainstem to the spinal cord is disrupted. Normally, the periaqueductal gray (PAG) and rostral ventromedial medulla (RVM) can dampen incoming pain signals. In chronic pain, this inhibitory control weakens, while facilitatory influences become dominant. Functional imaging studies reveal increased activity in brain regions involved in pain perception, emotion, and memory—such as the anterior cingulate cortex, insula, prefrontal cortex, and amygdala. These changes can link pain with negative emotions, anxiety, and catastrophizing, creating a vicious cycle that reinforces the pain experience.

Maladaptive Neuroplasticity

Neuroplasticity—the nervous system’s ability to reorganize its structure and function—underlies many chronic pain mechanisms. While plasticity is essential for learning and recovery, in chronic pain it becomes maladaptive. For example, cortical maps of the body can become distorted in conditions like phantom limb pain or CRPS, leading to referred sensations and difficulty localizing pain. Synaptic strengthening in pain circuits, sprouting of new connections, and loss of inhibitory interneurons all contribute to the chronicity of pain. Understanding neuroplasticity offers targets for therapies such as graded motor imagery, mirror therapy, and neuromodulation aimed at reversing these changes.

The Role of the Immune System and Systemic Factors

Physiological models increasingly recognize the involvement of the systemic immune response. Peripheral inflammation, whether from an autoimmune condition, infection, or metabolic dysfunction, can sensitize the nervous system both locally and centrally. For instance, elevated levels of circulating cytokines and chemokines have been found in patients with fibromyalgia and chronic widespread pain, suggesting a low‐grade systemic inflammatory state. Additionally, the hypothalamic‐pituitary‐adrenal (HPA) axis—the body’s stress response system—often becomes dysregulated, leading to altered cortisol rhythms and reduced anti‐inflammatory capacity. This intersection of immune, endocrine, and neural systems underscores the complexity of chronic pain and highlights why multimodal treatments are often necessary.

Emerging evidence also points to the role of autoimmunity in certain chronic pain syndromes. For example, some forms of complex regional pain syndrome may involve autoantibodies targeting neuronal receptors. Similarly, small fiber neuropathy can be associated with autoimmune markers. These findings open the door for immunomodulatory therapies in a subset of patients.

Integrating Physiological Models with Clinical Practice

Physiological models provide a rational basis for selecting and personalizing treatments. Rather than applying a one‐size‐fits‐all approach, clinicians can target the dominant mechanisms in each patient. The following interventions are guided by physiological understanding:

  • Pharmacological Agents: Nonsteroidal anti‐inflammatory drugs (NSAIDs) address peripheral inflammation, but their benefit is limited in central sensitization. Gabapentinoids (gabapentin, pregabalin), tricyclic antidepressants, serotonin‐norepinephrine reuptake inhibitors (SNRIs), and sodium channel blockers target neural hyperexcitability. Low‐dose naltrexone and other glial modulators are being investigated for neuroinflammatory pain.
  • Physical and Exercise Therapy: Graded exercise, manual therapy, and desensitization techniques help reverse peripheral and central sensitization by promoting normal movement patterns and reducing fear‐avoidance. Activity pacing prevents flares caused by overexertion.
  • Neuromodulation: Techniques such as transcutaneous electrical nerve stimulation (TENS), spinal cord stimulation (SCS), and transcranial direct current stimulation (tDCS) can interrupt abnormal pain signals and restore descending inhibitory control.
  • Psychological and Behavioral Interventions: Cognitive behavioral therapy (CBT), acceptance and commitment therapy (ACT), and biofeedback address maladaptive neuroplasticity by changing pain‐related thoughts, emotions, and behaviors. They also improve coping and reduce stress‐induced HPA dysregulation.
  • Diet and Lifestyle Modifications: Anti‐inflammatory diets, sleep hygiene, and stress management can reduce systemic inflammation and support healthy neuroplasticity.

Importantly, combining these approaches—multimodal pain management—often yields better outcomes than any single modality. Physiological models help explain why: pain involves multiple systems, so interventions targeting different mechanisms can have synergistic effects.

Current Research and Future Directions

Research into the physiology of chronic pain continues to evolve. Advanced neuroimaging techniques allow researchers to visualize brain connectivity changes and predict treatment responses. Genomics and proteomics are identifying biomarkers that could stratify patients into mechanistic subgroups. For example, specific gene variants related to catecholamine metabolism or cytokine production may influence pain sensitivity and treatment efficacy.

Emerging therapeutic targets include:

  • Glial modulators: Drugs that inhibit microglial activation, such as ibudilast and minocycline, are in clinical trials.
  • Ion channel blockers: Selective antagonists of Nav1.7, Nav1.8, and TRPV1 channels aim to dampen peripheral hyperexcitability without central side effects.
  • Neuromodulation protocols: Non‐invasive brain stimulation and closed‐loop spinal cord stimulators that adapt to neural activity.
  • Immunotherapies: Intravenous immunoglobulin and rituximab for autoimmune‐mediated pain.
  • Epigenetic interventions: Targeting histone modifications and DNA methylation that sustain maladaptive plasticity.

External resources for further reading include the International Association for the Study of Pain (IASP), the National Institute of Neurological Disorders and Stroke (NINDS), and the PubMed database for searchable literature on specific mechanisms.

Conclusion

Physiological models offer a rigorous, evidence‐based framework for understanding how chronic pain persists. By examining peripheral sensitization, central sensitization, neuroinflammation, altered pain pathways, and maladaptive neuroplasticity, researchers and clinicians can identify key drivers of pain syndromes. This mechanistic understanding leads to more targeted and effective treatments, moving beyond symptom management toward restoration of normal nervous system function. Continued interdisciplinary research—integrating neuroscience, immunology, genetics, and behavioral science—promises to further refine these models and improve outcomes for the millions of people living with chronic pain.